Assembly Biosciences, Inc.
ASMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426800
No open-market purchases or sales by Assembly Biosciences, Inc. insiders were filed in the last 90 days; 92 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Assembly Biosciences, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 75 | +7 |
| Shares | 13.7M | 572.9K | 13.6M | +417.3K (+3.2%) |
| Value | $466.7M | $19.5M | $376.4M | −$70.8M (−15.8%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Assembly Biosciences, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Capital Management LLC | 490,447 | $13.6M | 0.00% |
| HighVista Strategies LLC | 74,735 | $2.07M | 0.57% |
| Vanguard Fiduciary Trust Co | 71,606 | $1.99M | 0.00% |
| Wellington Management Group LLP | 26,496 | $735.3K | 0.00% |
| Squarepoint Ops LLC | 23,804 | $660.6K | 0.00% |
| Two Sigma Investments, LP | 20,550 | $570.3K | 0.00% |
| Vanguard Portfolio Management LLC | 17,723 | $491.8K | 0.00% |
| EntryPoint Capital, LLC | 12,384 | $343.7K | 0.10% |
| Brevan Howard Capital Management LP | 11,112 | $308.4K | 0.00% |
| Jump Financial, LLC | 10,917 | $302.9K | 0.00% |
| XTX Topco Ltd | 10,785 | $299.3K | 0.01% |
| American Century Companies Inc | 9,154 | $254.0K | 0.00% |
| Vanguard Global Advisers, LLC | 4,615 | $128.1K | 0.00% |
| Aquatic Capital Management LLC | 220 | $6.11K | 0.00% |
| Accent Capital Management, LLC | 142 | $3.94K | 0.00% |
| Fifth Third Bancorp | 57 | $1.58K | 0.00% |
| Royal Bank of Canada | 16 | $0 | 0.00% |
Sold out (10)
Institutions that held Assembly Biosciences, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Franklin Resources Inc | 210,528 | $7.16M |
| Superstring Capital Management LP | 65,273 | $2.22M |
| EAM Investors, LLC | 29,523 | $1.00M |
| Ellsworth Advisors, LLC | 29,735 | $889.4K |
| SEI Investments Co | 17,745 | $603.5K |
| Raymond James Financial Inc | 13,082 | $444.9K |
| Acadian Asset Management LLC | 12,446 | $422.0K |
| Charles Schwab Investment Management Inc | 6,704 | $228.0K |
| Farther Finance Advisors, LLC | 154 | $5.24K |
| Quadrant Capital Group LLC | 22 | $749 |
Not filed for Q1 2026 yet (1)
Institutions that held Assembly Biosciences, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 572,898 | $19.5M |